These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16650961)

  • 1. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
    Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
    Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
    Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer.
    Waas ET; Wobbes T; Lomme RM; Hendriks T
    Oncology; 2005; 68(2-3):256-62. PubMed ID: 16015042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
    Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS; Wu TL; Tsao KC; Sun CF
    Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer.
    Okada N; Ishida H; Murata N; Hashimoto D; Seyama Y; Kubota S
    Biochem Biophys Res Commun; 2001 Oct; 288(1):212-6. PubMed ID: 11594775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
    Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
    Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
    Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.